Pharmaceutical Spending Fell Slightly; A First, Says IMS Institute
This article was originally published in The Pink Sheet Daily
Executive Summary
IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.
You may also be interested in...
U.S. Drug Sales Top $329 Billion In 2013, Up 3.2% – IMS Report
IMS Health’s report on U.S. drug spending in 2013 shows a return to growth last year after a decline in 2012, with a lower impact of brands losing patent protection being an important factor, as well as brand price increases.
Early Drug Launches Off To a Strong Start So Far in 2013
2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.